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Abbreviation    Full term    
CC     Community Control  
CM      Cerebral Malaria  
DNA                  De-oxyribonucleic Acid  
SCA     Sickle cell anemia  
SMA      Severe Malarial Anemia 
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Abstract  
Retrospective studies suggest that high mortality in children with sickle cell anemia 
(SCA) and severe malaria. We assessed mortality in Ugandan children with severe 
malarial anemia (SMA, n= 232) or cerebral malaria (CM, n= 267) by HbS genotype. 
Admission and 2-year follow-up mortality did not differ among children with SMA who 
had HbSS vs HbAA (admission, 0/22, 0%, vs. 1/208, 0.5%; follow-up, 1/22, 4.5%; 7/207, 
3.4%, respectively, all P>0.6). The single child with CM and HbSS survived. The study 
findings highlight the need for large prospective studies of malaria-related mortality in 
children with SCA. 
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Introduction  
Sickle cell hemoglobin (HbS) is the most common pathological hemoglobin variant 
worldwide (1). Heterozygotes (HbAS) are usually asymptomatic and protected against 
malaria (5.6), whereas homozygotes (HbSS, sickle cell anemia, SCA) are prone to end 
organ damage (2-4) and, in many parts of sub-Saharan Africa, early death (2). Children 
with HbSS may not have an increased risk of developing malaria, but two studies with 
small numbers of children with SCA and severe malaria (n=5 and n=21, respectively) 
suggest they have a high mortality rate with severe malaria (7.8). To further address the 
question of mortality with severe malaria in children with SCA, we compared risk of 
inpatient and follow-up mortality according to HbS genotype in a prospectively enrolled 
cohort of children with severe malaria (cerebral malaria [CM] or severe malarial anemia 
[SMA]) and healthy community controls.  
 
Methods and Results  
Study participants. The study was carried out at Mulago National Referral Hospital in 
Kampala, Uganda (9). All participants were enrolled in a study assessing 
neurodevelopmental impairment in severe malaria, conducted from November 2008 to 
December 2013. Details of the methods of the primary study including inclusion criteria 
and study enrollment are described elsewhere (10). Briefly, children 18 months – 12 
years of age were enrolled. CM was defined as a child with unarousable coma and 
Plasmodium falciparum parasitemia on blood smear. SMA was defined a child with a 
hemoglobin level ≤ 5 g/dL and P. falciparum parasitemia on blood smear. Community 
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children were healthy children from the neighborhoods of children with severe malaria 
children. Children with known chronic disease, including known SCA, were excluded.  
Clinical management. Children with CM or SMA were managed according to Ugandan 
Ministry of Health treatment guidelines for malaria, which at time of study included 
intravenous quinine treatment followed by oral quinine. All children with SMA received 
a blood transfusion (20ml/kg of whole blood or 10ml/kg of packed red blood cells), 
usually within 2 hours of admission.  
Follow up. Study participants were followed up for 2 years after discharge from hospital 
to assess for illness, including malaria, readmissions and deaths. 
HbS testing: Genomic DNA was isolated from whole blood samples for SMA & CM 
patients or filter papers for CCs using the DNeasy Blood and tissue kit (Qiagen, Valencia, 
CA). The beta hemoglobin region of interest was amplified using specific primers. 
Children with HbSS were referred to the Mulago Hospital Sickle Cell Clinic, and HbSS 
was confirmed by hemoglobin electrophoresis. 
Statistical analysis. Analysis was done in STATA 12 (Stata Corporation). Proportions 
were compared with χ2 analysis and mean or median values with Student’s t-test or the 
Wilcoxon rank-sum test, respectively. Incidence rates were compared between groups by 
negative binomial regression. 
Ethical review. Written informed consent was obtained from parents or guardians of 
study participants. Institutional Review Boards for human studies at Makerere University 
and the University of Minnesota granted ethical approval for the study. 
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Admission findings. 267 children with CM, 232 children with SMA and 216 CC were 
enrolled and had samples available for HbS genotyping. HbAS was more frequent in CC 
(41, 19.0%) than in SMA (2, 0.9%) or CM (2, 0.8%), confirming the protective effect of 
HbAS against severe malaria. HbAS as compared to HbAA reduced the risk of severe 
malaria (SMA or CM) by 96% (odds ratio, [OR], 0.04, 95% confidence interval (CI), 
0.01, 0.10).  HbSS was more frequent in SMA (22, 9.5%) than CM (1, 0.4%) and was not 
present in CC. HbSS as compared to HbAA increased risk of SMA 28-fold (OR 27.9, 
95% CI, 3.7, 208.7). 
 
Among children with SMA, children with HbSS were older and had a higher white blood 
count than children with HbAA, however P. falciparum parasite density was similar in 
the two groups (Table 1). Among children with SMA, mortality did not differ between 
children with HbSS (0%) and children with HbAA (0.5%, Table 1). The one child with 
CM and HbSS survived. 
 
Follow up. Among CM survivors, 2/234 children (0.9%) died during 2-year follow-up. 
Both had HbAA. Among SMA survivors, 9 children (3.9%) died during follow-up, 1/22 
with HbSS (4.6%), 7/207 with HbAA (3.4%, P=0.77) and 1/2 with HbAS (50%). 
Compared to children with SMA and HbAA, children with SMA and HbSS had 
significantly higher incidence of post-discharge readmissions and a higher incidence of 
uncomplicated malaria that approached significance (P=0.06), but incidence of severe 
malaria readmissions did not differ significantly between children with HbSS and HbAA 
(Table 2).  
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Discussions 
We foundm in contrast to previous studies (7, 8), that children with SCA did not have 
increased inpatient mortality with severe malaria compared to children with HbAA. Even 
post-discharge mortality in children with HbSS and severe malaria did not differ 
significantly from that of children with HbAA (4.5% vs. 3.6%, P=0.77), though 
incidence of all-cause readmissions was higher with HbSS.  The findings bring in to 
question whether children with HbSS have an increased risk of mortality with severe 
malaria compared to children with HbAA. The findings must be interpreted with caution 
as the study did not include children with known SCA at the time of admission, and all 
children were >18 months of age, both factors which could select for a healthier 
population of children with SCA, as children with SCA in this setting are reported to 
have significant morbidity and mortality in the first 2 years of life (11, 12).  
 
Previous studies have shown that if blood transfusion service is readily available, as was 
the case in this study, mortality in SMA is generally low (13, 14). In the present study, 
this was the case regardless of the presence of concurrent SCA. Prior studies of severe 
malaria in children with SCA have shown a range of mortality: from 4/86 (4.6%) (15) to 
2/21 (9.5%) (8) of children with SCA admitted with parasitemia to 4/5 children (80%) 
admitted with WHO criteria for severe malaria (7). In the only other study assessing 
mortality in children with SMA and SCA, SMA was the primary complication of malaria, 
and none of the 38 children with SMA and SCA died (0% mortality) (15), a finding 
identical to the present study. Sample sizes of children with both severe malaria and SCA 
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have been small in all studies, emphasizing the need for large prospective studies of 
malaria morbidity and mortality in SCA. However, studies such as the present study, in 
which children with severe malaria are assessed for SCA, are another way of getting at 
the question, as these studies may “enrich” for children with severe malaria, which 
appears to be a relatively uncommon complication of SCA. 
 
In conclusion, our study findings suggest that in children >18 months of age with SCA, 
inpatient mortality from SMA, the most common form of severe malaria, is low and 
similar to that of children with HbAA if timely blood transfusion is provided, and that 
post-discharge mortality in children with SMA is also similar in children with HbSS vs. 
HbAA. However, the exclusion of children with known SCA is an important study 
limitation, as is the limited study sample size. Therefore, the present study is a call for 
large prospective studies of malaria morbidity and mortality in children with SCA to 
definitively address the extent to which severe malaria causes mortality in SCA.  
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Table 1. Demographic and clinical characteristics of children with severe malarial 
anemia, according hemoglobin AA (HbAA) or hemoglobin SS (HbSS) genotype 
HbAA, n=208 HbSS, n=22 P valuee 
Age, mean (SD) 2.7 (2.0, 4.1) 4.6 (3.7, 5.7) 0.007 
Sex, n male (%) 127 (61.1%) 13 (59.1%) 0.86 
Hemoglobin, g/dL, mean 
(SD) 3.7 (0.9) 3.7 (0.6) 0.38 
WBC, mean (SD) 12.9 (8.2) a 32.7 (16.0) < 0.001 
Thrombocytopenia, n (%) 109 (52.9%) a 8 (36.4%) 0.14 
P. falciparum parasite
density, parasites/µL, median
(25th, 75th percentile)
49,813b 
(14,678, 
229,046) 
41,586c 
(2,261, 140,672) 0.18 
Required oxygen, n (%) 19 (9.1%) 1 (4.6%) 0.47 
Blood culture, n positive (%) 22 (12.4%)d 1 (5.6%) d 0.39 
Given antibiotics, n (%) 63 (30.3%) 10 (45.5%) 0.15 
Death, n (%) 1 (0.5%) 0 (0%) 0.56 
WBC, white blood cell count; thrombocytopenia = platelet count < 100,000/µL 
a n for HbAA =206, b n for HbAA = 205, c n for HbSS = 21 
d n for HbAA = 177, n for HbSS = 18 
e Continuous variables compared by Student’s t-test except P. falciparum parasite density, 
compared by Wilcoxon rank-sum test. Categorical variables compared by χ2 analysis. 
Table 2.  Deaths, readmissions and outpatient clinic visits for children with SMA   
and HbAA or HbSS during  2 -year follow up  
Children with HbAS not shown because of low numbers (n=2) 
a Compared by χ2 analysis  
b Incidence rates compared by negative binomial regression. 
HbAA 
N= 207 
HbSS 
N= 22 P value 
Died, n (%) 7 (3.4%) 1 (4.5%) 0.77 a 
Incidence of deaths per 1000 person 
years  17.29 25.36 0.33
b 
Incidence of all cause readmissions 
per 1000 person years  51.89 126.81 0.05
b 
Incidence of severe malaria 
readmissions per 1000 person years 42.01 25.36 0.35
b 
Incidence of uncomplicated malaria 
visits per 1000 person years 106.26 202.90 0.06
b 
